Form 4: Doximity CFO Anna Bryson Executes Stock Option, Sells Shares Under 10b5-1 Plan
SEC Form 4
Doximity's CFO, Anna Bryson, exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan on February 11, 2025.
Summary
- On February 11, 2025, Anna Bryson, the Chief Financial Officer of Doximity, Inc., executed a series of transactions involving the company's stock.
- Bryson exercised stock options to acquire 95,000 shares of Class A Common Stock.
- Concurrently, she sold a total of 94,999 shares of Class A Common Stock at prices ranging from $74.9981 to $79.5821 per share.
- These sales were executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2024.
- Following these transactions, Bryson directly owns 329,386 shares of Class A Common Stock and 382,268 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The sentiment is neutral. The filing simply reports transactions executed under a pre-existing plan, which doesn't necessarily indicate a positive or negative outlook for the company.
Positives
- The sales were conducted under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.
Risks
- Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, potentially impacting the stock price.
Industry Context
Insider transactions are a common occurrence in publicly traded companies, and the use of Rule 10b5-1 plans is a standard practice to avoid accusations of illegal insider trading. Investors often monitor these transactions for insights into management's perspective on the company's future prospects.
Comparison to Industry Standards
- Comparing Doximity's insider trading activity to companies like Teladoc Health (TDOC) or GoodRx (GDRX) would provide context.
- For example, if executives at Teladoc or GoodRx are also selling shares under 10b5-1 plans, it could indicate a broader trend in the telehealth industry.
- Analyzing the volume and frequency of insider sales relative to the company's market capitalization and trading volume can offer further insights.
- Benchmarking Doximity's insider ownership levels against industry averages can also be informative.
Stakeholder Impact
- Shareholders may react to the news of insider selling, although the existence of a 10b5-1 plan mitigates potential concerns.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2021-02-01 | Stock option vests in 60 equal monthly installments after this date. |
| 2021-02-05 | Stock option was granted. |
| 2024-11-12 | Reporting Person adopted Rule 10b5-1 trading plan. |
| 2025-02-11 | Date of earliest transaction: stock option exercise and sale of shares. |
| 2025-02-13 | Date of Form 4 filing. |
| 2031-02-04 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.